Tags

Type your tag names separated by a space and hit enter

Validation of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath liquid-based pap test samples taken with different collection devices.
Sex Transm Dis. 2009 Sep; 36(9):581-3.ST

Abstract

Mocked samples of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) diluted in SurePath liquid-based Pap (L-Pap) fluid were detected by the APTIMA Combo 2 assay to end points 10-fold greater than dilutions in specimen transport media. Pooled L-Pap clinical specimens yielded CT-positive results after storage at room temperature for 10 days. Based on an infected patient standard for comparison, cervical swabs, urine, and SurePath L-Pap test samples collected with a SurePath cervical broom or ThinPrep cytobrush from 520 women then tested by APTIMA Combo 2 assay, detected 25 (4.8%) with CT, 5 (1.0%) with (GC), and 3 (0.6%) with both. Percent sensitivities (80-84), specificities (99.8-100), positive (99.5-100) and negative (99.2-99) predictive values of SurePath L-Pap for CT were validated as similar to those reported in a previously published multicenter trial. All values for GC were 100%. One collection device was not significantly better than the other.

Authors+Show Affiliations

St. Joseph's Healthcare/McMaster University, 50 Charlton Avenue East, Hamilton, Ontario, Canada. chernesk@mcaster.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

19661842

Citation

Chernesky, Max, et al. "Validation of the APTIMA Combo 2 Assay for the Detection of Chlamydia Trachomatis and Neisseria Gonorrhoeae in SurePath Liquid-based Pap Test Samples Taken With Different Collection Devices." Sexually Transmitted Diseases, vol. 36, no. 9, 2009, pp. 581-3.
Chernesky M, Jang D, Smieja M, et al. Validation of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath liquid-based pap test samples taken with different collection devices. Sex Transm Dis. 2009;36(9):581-3.
Chernesky, M., Jang, D., Smieja, M., Portillo, E., Ewert, R., Pritchard, C., MacEachern, D., Doucette, C., MacDonald, A., Kapala, J., Sumner, J., & Hill, C. (2009). Validation of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath liquid-based pap test samples taken with different collection devices. Sexually Transmitted Diseases, 36(9), 581-3. https://doi.org/10.1097/OLQ.0b013e3181a4c3fc
Chernesky M, et al. Validation of the APTIMA Combo 2 Assay for the Detection of Chlamydia Trachomatis and Neisseria Gonorrhoeae in SurePath Liquid-based Pap Test Samples Taken With Different Collection Devices. Sex Transm Dis. 2009;36(9):581-3. PubMed PMID: 19661842.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Validation of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath liquid-based pap test samples taken with different collection devices. AU - Chernesky,Max, AU - Jang,Dan, AU - Smieja,Marek, AU - Portillo,Eder, AU - Ewert,Ruth, AU - Pritchard,Cindy, AU - MacEachern,Diane, AU - Doucette,Christine, AU - MacDonald,Anne, AU - Kapala,Julius, AU - Sumner,Jeff, AU - Hill,Craig, PY - 2009/8/8/entrez PY - 2009/8/8/pubmed PY - 2009/12/16/medline SP - 581 EP - 3 JF - Sexually transmitted diseases JO - Sex Transm Dis VL - 36 IS - 9 N2 - Mocked samples of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) diluted in SurePath liquid-based Pap (L-Pap) fluid were detected by the APTIMA Combo 2 assay to end points 10-fold greater than dilutions in specimen transport media. Pooled L-Pap clinical specimens yielded CT-positive results after storage at room temperature for 10 days. Based on an infected patient standard for comparison, cervical swabs, urine, and SurePath L-Pap test samples collected with a SurePath cervical broom or ThinPrep cytobrush from 520 women then tested by APTIMA Combo 2 assay, detected 25 (4.8%) with CT, 5 (1.0%) with (GC), and 3 (0.6%) with both. Percent sensitivities (80-84), specificities (99.8-100), positive (99.5-100) and negative (99.2-99) predictive values of SurePath L-Pap for CT were validated as similar to those reported in a previously published multicenter trial. All values for GC were 100%. One collection device was not significantly better than the other. SN - 1537-4521 UR - https://www.unboundmedicine.com/medline/citation/19661842/Validation_of_the_APTIMA_Combo_2_assay_for_the_detection_of_Chlamydia_trachomatis_and_Neisseria_gonorrhoeae_in_SurePath_liquid_based_pap_test_samples_taken_with_different_collection_devices_ L2 - https://doi.org/10.1097/OLQ.0b013e3181a4c3fc DB - PRIME DP - Unbound Medicine ER -